Home / Letter From The Editor / Sept. 24, 2019

Sept. 24, 2019

Sep 24, 2019
 

This week the FDA approved the oral GLP-1 analog, semaglutide (Rybelus) for the treatment of type 2 diabetes. This is the first oral medication in the class that includes liraglutide, exenatide and dulaglutide. The secret of making this work orally is a medium chain fatty acid, and our intern Nour Salhab, Pharm.D. Candidate, USF College of Pharmacy, has found what that fatty acid is and examined the results that led to the groundbreaking new medication.

 

Dave Joffe

 

Editor-in-chief